Supporting Patient Communities


ENHANCING THE QUALITY OF LIFE FOR PATIENTS

For CSL, a focus on patients is a priority and promise. In 2015/16, CSL contributed US$9 million to local, national and international organisations to assist with patient support and education, disease awareness, early diagnosis, medical research and advocacy efforts.

We have collaborative relationships with patient groups around the world, such as the European Organisation for Rare Diseases and the US National Organization for Rare Disorders. On regional and market levels, we support numerous patient groups.

For example, over the reporting period, CSL Behring's commitment to enhancing the quality of life for patients in the conditions our therapies treat was as strong as ever. Our commitment to patient advocacy efforts in the US resulted in approximately $460,000 in contributions to patient organisations specific to supporting efforts in the public policy and advocacy arena. This is in addition to major non-policy-related patient program support that CSL provides (community building, awareness, diagnosis, information sharing and product access support programs). This support assisted patient groups representing individual's various conditions, including Alpha-1 antitrypsin deficiency, primary immunodeficiencies (PID), hereditary angioedema (HAE), neuropathies such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) and bleeding disorders.


IMPROVING ACCESS TO OUR BIOLOGICAL MEDICINES

CSL continues to work with international and national partners to deliver life-saving therapies to patients across the world. Our longstanding partnership with the World Federation of Hemophilia (WFH) continues to be strong with CSL marking World Hemophilia Day 2016 by contributing more than 1.5 million international units (IUs) of treatments for haemophilia A and/ or von Willebrand disease (see more on our support for the WFH in section 4.5 Access).

In June 2016, Seqirus announced the donation of 20,000 doses of seasonal influenza vaccine to the people of Fiji in order to help alleviate a spike in cases of severe influenza. At that time, the Fijian Ministry of Health reported a notable increase in hospitalisations due to seasonal influenza, as well as the number of pregnant women testing positive for influenza virus H1N1 and consequently suffering Severe Acute Respiratory Illness. Through a request facilitated by the World Health Organization’s Emerging Diseases Surveillance and Response Unit in Fiji, CSL was able to provide an immediate donation of influenza vaccine manufactured at our facility in Melbourne, Australia.

In addition, over the reporting period, CSL Behring provided US$4.9 million in product and/or financial support directly to US patients through our patient assistance programs. These access programs support qualified patients who are uninsured, underinsured or cannot afford their prescribed therapy.

SUPPORT FOR PATIENT COMMUNITIES 2015/16

BREAKDOWN OF TOTAL PATIENT COMMUNITY CONTRIBUTIONS


  • PATIENT ORGANISATION SUPPORT – 54%
  • PATIENT ASSISTANCE/HUMANITARIAN ACCESS PROGRAMS – 46%